AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23886594
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (HCTZ and ATEN)
Trial: 21975176
Drug: Allergy vaccination
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergy vaccination (specific immunotherapy)
Trial: 15725286
Drug: 0.04% MDBGN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% MDBGN applied once daily
Trial: 15725286
Drug: 0.01% MDBGN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% MDBGN applied 4 times daily
Trial: 10383522
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Trial: 8710739
Drug: Rac-talinolol 30
RxNorm normalized name: talinolol
DrugBank: Talinolol (DB11770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rac-talinolol 30 mg i.v. and 100 mg p.o. in cholecystectomized patients
Trial: 8710739
Drug: Rac-talinolol 25
RxNorm normalized name: talinolol
DrugBank: Talinolol (DB11770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rac-talinolol 25 mg, 50 mg, 100 mg, and 400 mg p.o. in healthy volunteers
Trial: 1987387
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg) + Dipyridamole (150 mg)
Trial: 6352081
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (500,000 IU over 15 min)
Trial: 6352081
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (1 million IU over 45 min)
Trial: 28856435
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of triamcinolone
Trial: 18654082
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg/day) - fully informed group
Trial: 18654082
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg/day) - partially informed group
Trial: 18654082
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg/day) - not informed group
Trial: 15387395
Drug: Triplicate Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplicate Prescription Program (TPP) in New York
Trial: 3127243
Drug: Terguride 1
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride 1 mg
Trial: 2616602
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg
Trial: 3127243
Drug: Terguride lower
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride lower doses
Trial: 28231782
Drug: D3 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 daily
Trial: 28231782
Drug: D3 2-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 2-weekly
Trial: 28231782
Drug: D2 daily
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 daily
Trial: 28231782
Drug: D2 2-weekly
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 2-weekly
Trial: 28231782
Drug: D2 4-weekly
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 4-weekly
Trial: 25979180
Drug: School-based sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based sleep education programme (four classroom lessons delivered weekly)
Trial: 20519876
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost
Trial: 20956120
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost in combination with oral bosentan
Trial: 16846448
Drug: Ding Chuan
RxNorm normalized name: Ding xiang
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ding Chuan Tang (DCT) 6.0 g daily for 12 weeks
Trial: 12968988
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg orally once daily for 5 days
Trial: 8375733
Drug: Natural interferon-beta
RxNorm normalized name: interferon beta natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural interferon-beta (IFN-beta) at two different dose levels (2 x 10(6) IU or 6 x 10(6) IU im 3 times/week for 1 week)
Trial: 26922655
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication discontinuation
Trial: 26922655
Drug: Successful discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful discontinuation (defined as no relapse within the observation period)
Trial: 26922655
Drug: Successful discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful discontinuation (defined as no relapse and symptomatic remission at 12-month follow-up)
Trial: 26922655
Drug: Discontinuation predictors
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation predictors
Trial: 26922655
Drug: Successful discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful discontinuation predictors (definition a)
Trial: 26922655
Drug: Successful discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful discontinuation predictors (definition b)
Trial: 22813676
Drug: WPS (Workplace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPS (Workplace Solutions) intervention group
Trial: 18942901
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg tid; n = 12)
Trial: 16158479
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (n=74)
Trial: 12934778
Drug: Transdermal oxybutynin
RxNorm normalized name: oxybutynin Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oxybutynin (Oxytrol, 3.9 mg/d)
Trial: 12934778
Drug: Extended-release oral
RxNorm normalized name: Carbinoxamine Maleate Extended-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oral oxybutynin (Ditropan XL, 10 mg)
Trial: 10393376
Drug: Trimethoprim-sulfamethoxazole (trimethoprim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (trimethoprim, 320 mg/day; sulfamethoxazole, 1,600 mg/day)
Trial: 10393376
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics (control group)
Trial: 8894571
Drug: Zidovudine (AZT)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (AZT) 1 g/day
Trial: 3318145
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg PG E2 endocervically
Trial: 3318145
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PG E2 intravaginally
Trial: 26455718
Drug: Artificial endometrial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial endometrial cycle treatment (AEC)
Trial: 17977859
Drug: Ropivacaine 0.165%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.165% with sufentanil 1 microg ml(‐1)
Trial: 17977859
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% with sufentanil 1 microg ml(‐1)
Trial: 16365120
Drug: Clamping the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clamping the drains after intra‐articular injection of saline with 1:500 000 adrenaline
Trial: 7674690
Drug: Judicious prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Judicious prescription of therapies in stepwise fashion
Trial: 2469338
Drug: Hypertonic saline‐dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline‐dextran solution
Trial: 23328847
Drug: Radio-frequency nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio-frequency nerve ablation (RFNA) after crossover from sham treatment
Trial: 29525602
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bevacizumab
Trial: 24923077
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bevacizumab
Trial: 14969649
Drug: Glyburide/metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin plus rosiglitazone (4 mg once daily)
Trial: 14969649
Drug: Glyburide/metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin plus rosiglitazone
Trial: 14969649
Drug: Glyburide/metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin plus placebo
Trial: 9403284
Drug: Erythromycin 1
RxNorm normalized name: erythromycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1 g b.i.d. for 5 days
Trial: 9403284
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg qd for 5 days
Trial: 8144986
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone (4 Gy per fraction, three fractions per week to a total dose of 24 Gy)
Trial: 31084381
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (400 mg daily for 12 weeks)
Trial: 24180479
Drug: i.v. mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. mitoxantrone (MTX), oral vinorelbine, or oral etoposide, together with oral prednisone
Trial: 23242572
Drug: NR-INF-02 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NR-INF-02 (500 mg twice daily)
Trial: 23242572
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 mg twice daily)
Trial: 23242572
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulphate (GS) (750 mg twice daily)
Trial: 23242572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NR-INF-02 and GS
Trial: 18083691
Drug: ILF (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILF (irinotecan 150 mg/m², leucovorin 20 mg/m², 5-FU 1000 mg/m² on days 1 and 2)
Trial: 18083691
Drug: PILF (ILF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PILF (ILF plus cisplatin 30 mg/m² on day 2)
Trial: 12660333
Drug: Benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (20 mg once daily)
Trial: 15533733
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg once daily)
Trial: 12660333
Drug: Dual blockade
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual blockade (20 mg benazepril + 80 mg valsartan)
Trial: 10971305
Drug: Stevioside (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stevioside (250 mg) thrice daily
Trial: 8832991
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg equivalent)
Trial: 1449107
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) at 540 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Trial: 1449107
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) at 450 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Trial: 6150276
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg or 150 mg kanamycin plus gentamicin eye ointment (for 3 days)
Trial: 6150276
Drug: Single-dose kanamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose kanamycin with saline eye washes (for 3 days)
Trial: 6150276
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg kanamycin plus chloramphenicol eye drops
Trial: 28443675
Drug: Palmar proximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmar proximal injection approach
Trial: 28443675
Drug: Palmar distal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmar distal injection approach
Trial: 28443675
Drug: Webspace injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Webspace injection approach
Trial: 26676838
Drug: O2-O3 intradiscal
RxNorm normalized name: O3-Methylmorphine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O2-O3 intradiscal injection
Trial: 19012050
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated estrogen (CE) + 2.5 mg medroxyprogesterone acetate (MPA)/day
Trial: 19012050
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tibolone/day
Trial: 9023459
Drug: Inulin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (7 g)
Trial: 9023459
Drug: Oligofructose (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (17 g)
Trial: 9023459
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (7 g of sucrose)
Trial: 8420063
Drug: OKT3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 plus azathioprine and steroids for 14 days with delayed addition of cyclosporine on day 11
Trial: 8420063
Drug: Conventional immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppression (steroids, azathioprine, and cyclosporine)
Trial: 3106632
Drug: 125 mg/day
RxNorm normalized name: infigratinib phosphate 125 mg/day (100 mg x 1 and 25 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/day D‐penicillamine
Trial: 3106632
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg D‐penicillamine
Trial: 31237134
Drug: OM3-FAs 4,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3-FAs 4,000 mg plus atorvastatin 20 mg
Trial: 31237134
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg plus placebo
Trial: 28039060
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral calcium supplementation
Trial: 25365032
Drug: Caffeinated carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated carbohydrate gel (CC) - 21.6 g carbohydrate, 100 mg caffeine
Trial: 25365032
Drug: Carbohydrate-only placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-only placebo gel (CP) - 21.6 g carbohydrate, 0 mg caffeine
Trial: 23728830
Drug: ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20 mg
Trial: 23866306
Drug: doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doubling the baseline statin dose (simvastatin 40 mg or atorvastatin 20 mg)
Trial: 19125756
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (120,000 IU each; three doses, administered fortnightly)
Trial: 28361822
Drug: Clozapine (200-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (200-600 mg/day)
Trial: 11697576
Drug: Olanzapine (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-30 mg/day)
Trial: 11697576
Drug: Risperidone (8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (8-16 mg/day)
Trial: 11697576
Drug: Haloperidol (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10-40 mg/day)
Trial: 11697576
Drug: Sulpiride (600-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (600-1600 mg/day)
Trial: 11788429
Drug: Drug-free state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free state
Trial: 8426714
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg triazolam with nitrous oxide
Trial: 8426714
Drug: Diazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (mean dose = 19.3 mg)
Trial: 23596051
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (Gb) treatment
Trial: 18254761
Drug: IN morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN morphine 3.75 mg, 7.5 mg, 15 mg, or 30 mg
Trial: 18254761
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine 7.5 mg
Trial: 18254761
Drug: IN morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN morphine 7.5 mg
Trial: 18254761
Drug: IN morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN morphine 15 mg
Trial: 11220430
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg(‐1) of oral transmucosal midazolam mixed with strawberry syrup
Trial: 11220430
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received plain syrup 0.08 ml x kg(‐1)
Trial: 11220430
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg(‐1) of oral transmucosal midazolam
Trial: 8193524
Drug: Matrix controlled
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix controlled clonidine transdermal (C‐TD) system
Trial: 2419009
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Trial: 29451020
Drug: Crizotinib, ceritinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib, ceritinib, and alectinib (previous treatments)
Trial: 22396387
Drug: Active conservative
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active conservative treatment for urinary incontinence (UI)
Trial: 12049567
Drug: 500 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 rad (5 Gy) irradiation at 1 minute post-treatment
Trial: 12049567
Drug: 500 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 rad (5 Gy) irradiation at 2 minutes post-treatment
Trial: 12049567
Drug: 500 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 rad (5 Gy) irradiation at 3 minutes post-treatment
Trial: 10607256
Drug: Thymosin alpha1
RxNorm normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha1 (Talpha1) 1.6 mg, twice weekly for 6 months
Trial: 10607256
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice weekly for 6 months
Trial: 8578549
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (ASA)
Trial: 2338114
Drug: cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 600 mg
Trial: 9655654
Drug: Transdermal 17‐beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17‐beta‐oestradiol (100 microg per 24 h)
Trial: 29404725
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg + MTX
Trial: 29404725
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg + MTX
Trial: 27600829
Drug: Sarilumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab (both doses)
Trial: 31925799
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily
Trial: 22775481
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oral E(2) 2 mg/NETA 1 mg daily
Trial: 21915249
Drug: Methylcellulose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose placebo gel
Trial: 18353393
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg 3 times a day)